leadf
logo-loader
viewIntrommune Therapeutics

Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval process

Intrommune Therapeutics CEO Michael Nelson sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The New York-based biotechnology company is developing is developing an oral mucosal immunotherapy treatment platform to treat food allergies including peanut allergies.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Nano One launches M2CAM and named as one of the TSX Venture top 50 companies

Nano One (CVE: NNO- OTC: NNOMF) CEO Dan Blondal joined Steve Darling from Proactive to share news, Nano One has been named of the TSX Ventures top 50 companies. Blondal shares with Proactive what that means for the company and he also shares with Proactive how their proprietary coated single...

11 hours, 12 minutes ago

2 min read